AZATHIOPRINE-50 TABLET
Land: Canada
Taal: Engels
Bron: Health Canada
Productkenmerken
(SPC)
11-02-2020
Sommige documenten voor dit product zijn momenteel niet beschikbaar, u kunt een verzoek sturen naar onze klantenservice en we zullen u hiervan op de hoogte stellen zodra we ze kunnen verkrijgen.
Verzend verzoek.
Verzend verzoek.
Werkstoffen:
AZATHIOPRINE
Beschikbaar vanaf:
PRO DOC LIMITEE
ATC-code:
L04AX01
INN (Algemene Internationale Benaming):
AZATHIOPRINE
Dosering:
50MG
farmaceutische vorm:
TABLET
Samenstelling:
AZATHIOPRINE 50MG
Toedieningsweg:
ORAL
Eenheden in pakket:
100
Prescription-type:
Prescription
Therapeutisch gebied:
IMMUNOSUPPRESSIVE AGENTS
Product samenvatting:
Active ingredient group (AIG) number: 0101830001; AHFS:
Autorisatie-status:
CANCELLED POST MARKET
Autorisatie datum:
2023-07-10
Productkenmerken
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
AZATHIOPRINE-50
AZATHIOPRINE TABLETS USP
50 MG
IMMUNOSUPPRESSIVE AGENT
PRO DOC LTÉE
Date of Revision:
2925, Boul. Industriel,
February 11, 2020
Laval, Quebec
H7L 3W9
Submission Control No.: 235658
_AZATHIOPRINE-50 Product Monograph _
_ _
Page 2 of 29
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................................
3
SUMMARY PRODUCT INFORMATION
..................................................................................................
3
INDICATIONS AND CLINICAL USE
........................................................................................................
3
CONTRAINDICATIONS
.............................................................................................................................
3
WARNINGS AND PRECAUTIONS
............................................................................................................
4
ADVERSE REACTIONS
..............................................................................................................................
9
DRUG INTERACTIONS
............................................................................................................................
11
DOSAGE AND ADMINISTRATION
........................................................................................................
12
OVERDOSAGE
..........................................................................................................................................
13
ACTION AND CLINICAL PHARMACOLOGY
......................................................................................
13
STORAGE AND STABILITY
....................................................................................................................
15
SPECIAL HANDLING INSTRUCTIONS
.................................................................................................
15
DOSAGE FORMS, COMPOSITION AND PACKAGING
..................................
Lees het volledige document
